Universität zu Köln

Hentrich, Marcus, Berger, Marcel, Wyen, Christoph, Siehl, Jan, Rockstroh, Juergen K., Mueller, Markus, Faetkenheuer, Gerd, Seidel, Elisabeth, Nickelsen, Maike, Wolf, Timo, Rieke, Ansgar, Schuermann, Dirk, Schmidmaier, Ralf, Planker, Manfred, Alt, Juergen, Mosthaf, Franz, Engert, Andreas, Arasteh, Keikawus and Hoffmann, Christian (2012). Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. J. Clin. Oncol., 30 (33). S. 4117 - 4124. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral therapy, standard therapy is still poorly defined. This prospective study investigates a stage- and risk-adapted treatment strategy in patients with HIV-HL. Patients and Methods Patients with early favorable HIV-HL received two to four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of involved-field (IF) radiation. In patients with early unfavorable HIV-HL, four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP baseline) or four cycles of ABVD + 30 Gy of IF radiation were administered. Six to eight cycles of BEACOPP baseline were given in patients with advanced-stage HIV-HL. In patients with advanced HIV infection, BEACOPP was replaced with ABVD. Results Of 108 patients (including eight female patients) included in the study, 23 (21%) had early favorable HL, 14 (13%) had early unfavorable HL, and 71 (66%) had advanced-stage HL. The median CD4 count at HL diagnosis was 240/mu L. The complete remission rates for patients with early favorable, early unfavorable, and advanced-stage HL were 96%, 100%, and 86%, respectively. The 2-year progression-free survival of the entire study population was 91.7%. Eleven patients (11%) have died, and treatment-related mortality was 5.6%. The 2-year overall survival rate was 90.7% with no significant difference between early favorable (95.7%), early unfavorable (100%), and advanced-stage HL (86.8%). Conclusion In patients with HIV-HL, stage- and risk-adapted treatment is feasible and effective. The prognosis for patients with HIV-HL may approach that of HIV-negative patients with HL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hentrich, Marcus UNSPECIFIED UNSPECIFIED UNSPECIFIED Berger, Marcel UNSPECIFIED UNSPECIFIED UNSPECIFIED Wyen, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Siehl, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Rockstroh, Juergen K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, Gerd UNSPECIFIED UNSPECIFIED UNSPECIFIED Seidel, Elisabeth UNSPECIFIED UNSPECIFIED UNSPECIFIED Nickelsen, Maike UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Timo UNSPECIFIED UNSPECIFIED UNSPECIFIED Rieke, Ansgar UNSPECIFIED UNSPECIFIED UNSPECIFIED Schuermann, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmidmaier, Ralf UNSPECIFIED UNSPECIFIED UNSPECIFIED Planker, Manfred UNSPECIFIED UNSPECIFIED UNSPECIFIED Alt, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Mosthaf, Franz UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Arasteh, Keikawus UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-478569
DOI:	10.1200/JCO.2012.41.8137
Journal or Publication Title:	J. Clin. Oncol.
Volume:	30
Number:	33
Page Range:	S. 4117 - 4124
Date:	2012
Publisher:	AMER SOC CLINICAL ONCOLOGY
Place of Publication:	ALEXANDRIA
ISSN:	1527-7755
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ACTIVE ANTIRETROVIRAL THERAPY; STEM-CELL TRANSPLANTATION; PROGNOSTIC-FACTORS; PATIENTS PTS; STANFORD-V; DISEASE; IMMUNODEFICIENCY; CHEMOTHERAPY; RADIOTHERAPY; SURVIVAL Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47856